Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Depression, Depression, Major Depression Disorder (MDD) |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 95 |
| Updated: | 2/14/2019 |
| Start Date: | March 2014 |
| End Date: | October 2019 |
This Randomized Clinical Trial (RCT) compares outcomes in patients with major depressive
disorder (MDD) treated according to the patient's CYP2D6 genotype status versus empiric
"standard-of-care" psychotropic therapy. The hypothesis is that provision of medication based
on the functional status of the patient's CYP2D6 enzyme inferred from genotype results within
48 hours of admission to treating clinicians will, through refined selection of psychotropic
medication during hospitalization, decrease length of psychiatric hospitalization stay and
decrease the rate of 30 day re-admission.
The trial setting is the Hartford Hospital Institute of Living (IOL). The IOL operated the
Clinical Evaluation and Monitoring System (CEMS), an innovative electronic messaging system
developed by Co-Investigator Dr. J.W. Goethe. The Hartford Hospital Genetics Research Center
(GRC) performs the genotype testing. CYP2D6 genotype analysis detects all known polymorphisms
that result in an enzyme with sub-normal or supra-normal function. In this study, CEMS
transmits clinically actionable guidance based on the patient's genotype to the clinician,
advancing the medication alerts in real time.
The RCT will test the effects of timely incorporation of medication recommendations based on
CYP2D6 genotype into CEMS. The RCT randomizes patients to standard therapy (Group S) for whom
CYP2D6 genetic information is determined but not transmitted to the treating clinician,
allowing psychotropic therapy to be empirically determined, and to genetically guided therapy
(Group G) where genotyping result and treatment recommendations are furnished via CEMS to the
clinician within 48 hours of admission. For patients in Group G who are poor or rapid
metabolizers, medications primarily metabolized by the CYP2D6 enzyme are proscribed.
The primary outcome is hospital length of stay and the secondary outcome, the frequency of 30
day hospital readmission. Additional genetic stratification of both Group S and Group G will
allow investigation of specific psychotropic usage.
The expected benefits are (1) quantitative understanding of the effect of providing CYP2D6
pharmacogenetic information on length of hospitalization, 30 day readmission rate, and
associated costs; and (2) objective benchmarking for the comparative effectiveness of CYP2D6
genotyping for guiding psychotropic therapy.
disorder (MDD) treated according to the patient's CYP2D6 genotype status versus empiric
"standard-of-care" psychotropic therapy. The hypothesis is that provision of medication based
on the functional status of the patient's CYP2D6 enzyme inferred from genotype results within
48 hours of admission to treating clinicians will, through refined selection of psychotropic
medication during hospitalization, decrease length of psychiatric hospitalization stay and
decrease the rate of 30 day re-admission.
The trial setting is the Hartford Hospital Institute of Living (IOL). The IOL operated the
Clinical Evaluation and Monitoring System (CEMS), an innovative electronic messaging system
developed by Co-Investigator Dr. J.W. Goethe. The Hartford Hospital Genetics Research Center
(GRC) performs the genotype testing. CYP2D6 genotype analysis detects all known polymorphisms
that result in an enzyme with sub-normal or supra-normal function. In this study, CEMS
transmits clinically actionable guidance based on the patient's genotype to the clinician,
advancing the medication alerts in real time.
The RCT will test the effects of timely incorporation of medication recommendations based on
CYP2D6 genotype into CEMS. The RCT randomizes patients to standard therapy (Group S) for whom
CYP2D6 genetic information is determined but not transmitted to the treating clinician,
allowing psychotropic therapy to be empirically determined, and to genetically guided therapy
(Group G) where genotyping result and treatment recommendations are furnished via CEMS to the
clinician within 48 hours of admission. For patients in Group G who are poor or rapid
metabolizers, medications primarily metabolized by the CYP2D6 enzyme are proscribed.
The primary outcome is hospital length of stay and the secondary outcome, the frequency of 30
day hospital readmission. Additional genetic stratification of both Group S and Group G will
allow investigation of specific psychotropic usage.
The expected benefits are (1) quantitative understanding of the effect of providing CYP2D6
pharmacogenetic information on length of hospitalization, 30 day readmission rate, and
associated costs; and (2) objective benchmarking for the comparative effectiveness of CYP2D6
genotyping for guiding psychotropic therapy.
Over 1.4 million hospitalizations for mental health conditions occur annually in the United
States (3.4% of all hospitalizations), and more than half are for major depressive disorder
(MDD). Remarkably, of the 30 antidepressant and antipsychotic medications available to treat
MDD, nearly 50% are primarily metabolized by the liver enzyme encoded by the CYP2D6 gene. The
CYP2D6 gene is notable for common sequence and structural polymorphisms which markedly affect
the enzyme's capacity, causing a decrease or increase in drug metabolism in 60% of patients,
and creating challenges for therapeutic management. The metabolic alterations caused by
CYP2D6 gene polymorphisms may require longer hospitalizations due to "trial-and-error"
prescribing, which delays improvement in health status and consumes resources. Reliable
genotype testing is now available to detect an array of 21 gene alterations. Prescribing
psychotropics using knowledge of the patient's CYP2D6 gene status is potentially cost
effective.
For this research, the Genetics Research Center performs the CYP2D6 genotyping, and the
Institute of Living's Clinical Evaluation and Monitoring System (CEMS) transmits explicit
alerts regarding prescription or proscription of specific psychotropics.
The RCT will compare outcomes in patients whose treatment is guided by CYP2D6 functional
status and pharmacogenetic alerts versus standard-of-care treatment to test the hypothesis
that the provision of clinically actionable prescription or proscription information can
decrease hospitalization length of stay and reduce subsequent readmission.
Using funds from AHRQ R01 HS022304-01, the RCT will enroll patients admitted to IOL over the
next 5 years with a diagnosis of MDD and who are receiving psychotropic therapy at the time
of admission or who will receive psychotropic therapy during hospitalization. Patients will
be assigned to standard-of-care pharmacotherapy (Group S), where CYP2D6 genotype is
determined but not transmitted to the clinician and psychotropic therapy follows the
institutional norm. Patients will be assigned to genetically-guided pharmacotherapy (Group G)
where pharmacogenetic alerts based on CYP2D6 genotype are furnished via CEMS to the clinician
within 48 hours of admission. Genotyping encompasses 19 common polymorphisms in CYP2D6 and
their quantification into a drug metabolism reserve index to establish levels of sub-normal
function (poor metabolizer) or supra-normal function (rapid metabolizer). For the estimated
40% of patients in Group G who are poor or rapid metabolizers, CEMS will proscribe
medications which are major CYP2D6 substrates.
The PI is Dr. Gualberto Ruaño, Director of GRC, and the lead clinician and Co-I is Dr. John
Goethe, retired Director of IOL's Burlingame Research Center. Drs. Ruaño and Goethe have
previously collaborated for 15 years on the pharmacogenetics of CYP450 and psychotropics. Dr.
Theodore Holford of Yale University serves as statistical consultant.
The expected benefits are quantitative understanding of CYP2D6 pharmacogenetic information on
outcomes and associated costs of psychiatric hospitalization. Importantly, this Program will
provide objective benchmarking data for the comparative effectiveness of CYP2D6 genotyping
for guiding psychiatric inpatient prescription.
The Specific Aims are:
1. RCT RECRUITMENT: To recruit patients with Major Depressive Disorder admitted to the IOL
and randomly assign to Group G (genetically guided) and to Group S (standard of care).
2. RCT INTERVENTION: To conduct CYP2D6 genotyping of null alleles (*3, *4, *4XN, *5, *6,
*7, *8, *11, *12, *14, *15), deficient alleles (*9, *10, *17, *29, *41), functional
variants (*1, *2), and rapid alleles (*1XN, *2XN, *2a, *35) for all patients. In Group G
the genotyping result is communicated to the treating clinician with prescription and
proscription alerts for CYP2D6 substrate drugs; in Group S, the genotype is withheld.
CEMS furnished results for 826 patients.
3. PRIMARY ENDPOINT: To compare length of hospitalization for all patients in Groups G vs.
S.
4. SECONDARY ENDPOINT: To compare the rates of 30-day psychiatric hospital readmission in
Group G vs. S.
5. ANCILLARY STUDIES: To assess the impact of genetic stratification in Groups G vs. S.
with regard to the primary and secondary endpoints and specific drug utilization
(removals, additions, co-prescriptions).
States (3.4% of all hospitalizations), and more than half are for major depressive disorder
(MDD). Remarkably, of the 30 antidepressant and antipsychotic medications available to treat
MDD, nearly 50% are primarily metabolized by the liver enzyme encoded by the CYP2D6 gene. The
CYP2D6 gene is notable for common sequence and structural polymorphisms which markedly affect
the enzyme's capacity, causing a decrease or increase in drug metabolism in 60% of patients,
and creating challenges for therapeutic management. The metabolic alterations caused by
CYP2D6 gene polymorphisms may require longer hospitalizations due to "trial-and-error"
prescribing, which delays improvement in health status and consumes resources. Reliable
genotype testing is now available to detect an array of 21 gene alterations. Prescribing
psychotropics using knowledge of the patient's CYP2D6 gene status is potentially cost
effective.
For this research, the Genetics Research Center performs the CYP2D6 genotyping, and the
Institute of Living's Clinical Evaluation and Monitoring System (CEMS) transmits explicit
alerts regarding prescription or proscription of specific psychotropics.
The RCT will compare outcomes in patients whose treatment is guided by CYP2D6 functional
status and pharmacogenetic alerts versus standard-of-care treatment to test the hypothesis
that the provision of clinically actionable prescription or proscription information can
decrease hospitalization length of stay and reduce subsequent readmission.
Using funds from AHRQ R01 HS022304-01, the RCT will enroll patients admitted to IOL over the
next 5 years with a diagnosis of MDD and who are receiving psychotropic therapy at the time
of admission or who will receive psychotropic therapy during hospitalization. Patients will
be assigned to standard-of-care pharmacotherapy (Group S), where CYP2D6 genotype is
determined but not transmitted to the clinician and psychotropic therapy follows the
institutional norm. Patients will be assigned to genetically-guided pharmacotherapy (Group G)
where pharmacogenetic alerts based on CYP2D6 genotype are furnished via CEMS to the clinician
within 48 hours of admission. Genotyping encompasses 19 common polymorphisms in CYP2D6 and
their quantification into a drug metabolism reserve index to establish levels of sub-normal
function (poor metabolizer) or supra-normal function (rapid metabolizer). For the estimated
40% of patients in Group G who are poor or rapid metabolizers, CEMS will proscribe
medications which are major CYP2D6 substrates.
The PI is Dr. Gualberto Ruaño, Director of GRC, and the lead clinician and Co-I is Dr. John
Goethe, retired Director of IOL's Burlingame Research Center. Drs. Ruaño and Goethe have
previously collaborated for 15 years on the pharmacogenetics of CYP450 and psychotropics. Dr.
Theodore Holford of Yale University serves as statistical consultant.
The expected benefits are quantitative understanding of CYP2D6 pharmacogenetic information on
outcomes and associated costs of psychiatric hospitalization. Importantly, this Program will
provide objective benchmarking data for the comparative effectiveness of CYP2D6 genotyping
for guiding psychiatric inpatient prescription.
The Specific Aims are:
1. RCT RECRUITMENT: To recruit patients with Major Depressive Disorder admitted to the IOL
and randomly assign to Group G (genetically guided) and to Group S (standard of care).
2. RCT INTERVENTION: To conduct CYP2D6 genotyping of null alleles (*3, *4, *4XN, *5, *6,
*7, *8, *11, *12, *14, *15), deficient alleles (*9, *10, *17, *29, *41), functional
variants (*1, *2), and rapid alleles (*1XN, *2XN, *2a, *35) for all patients. In Group G
the genotyping result is communicated to the treating clinician with prescription and
proscription alerts for CYP2D6 substrate drugs; in Group S, the genotype is withheld.
CEMS furnished results for 826 patients.
3. PRIMARY ENDPOINT: To compare length of hospitalization for all patients in Groups G vs.
S.
4. SECONDARY ENDPOINT: To compare the rates of 30-day psychiatric hospital readmission in
Group G vs. S.
5. ANCILLARY STUDIES: To assess the impact of genetic stratification in Groups G vs. S.
with regard to the primary and secondary endpoints and specific drug utilization
(removals, additions, co-prescriptions).
Inclusion Criteria:
1. Men or women aged 18 y or older.
2. Patients who have been admitted to the Institute of Living and having a diagnosis of
major depressive disorder.
3. The ability to understand the requirements of the study.
4. The ability to comply with study procedures and protocol.
5. A woman is eligible to enter the study if she is of child-bearing potential and not
pregnant or nursing.
Exclusion Criteria:
1. Children and adolescents
2. Hospital admission within previous 30 d of current admission.
3. History of dementia or Alzheimer's disease
4. History of chronic kidney disease (CKD).
5. Surgery within 6 wk.
6. Ischemic stroke within 6 wk.
7. Any history of hemorrhagic stroke or subarachnoid hemorrhage.
8. Current enrollment in an investigational drug or device study that has not reached the
time of the primary end point
We found this trial at
1
site
Click here to add this to my saved trials
